10x Genomics Puts Single Cell Analysis Within Reach of All With Low Throughput Gene Expression Kit

PLEASANTON, Calif., April 01, 2021 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG) today announced the launch of its Chromium Single Cell Gene Expression Low Throughput (LT) Kit, a new offering designed to put the power of single cell analysis within the reach of more scientists than ever before. The new LT Kit reduces the startup cost for a single experiment, enabling a broader base of scientists to conduct single cell analysis. In addition, scientists now have the ability to use the 10x Genomics Cloud to perform a standard analysis of every sample at no additional cost, accelerating findings in a cost-effective manner.

As a leader in single cell sequencing, 10x Genomics continues to develop products to accelerate access and affordability for a broader base of scientists across academia, research institutions, and pharmaceutical companies. Today’s news gives scientists a range of options to conduct single cell analysis from their first starter project of a few hundred cells to standard scale experiments of thousands to tens of thousands of cells all the way to high throughput million cell studies with the company’s next-generation Chromium X instrument, slated for release later this year.

10x Genomics recently started shipping its Single Cell Gene Expression with CellPlex, making single cell analysis on its standard kits more affordable. The CellPlex solution allows the multiplexing of up to 96 samples in a single chip, giving scientists the ability to drive larger experiments as they scale up from the LT Kit. CellPlex will also integrate into the company’s high throughput kits to be released with Chromium X.

“Studying biology at the single cell level is at the core of any scientist's toolbox to make discoveries for the most pressing diseases and to advance human health,” said 10x Genomics Co-founder and Chief Scientific Officer Ben Hindson. “With the 10x Genomics Low Throughput Gene Expression Kit, we are democratizing single cell analysis, and we hope it catalyzes a whole new set of discoveries never imagined before.”

“We are excited that the 10x Genomics Low Throughput kit will enable faster tech dev by allowing us to pilot and optimize experimental conditions,” said Joseph Replogle of the Whitehead Institute for Biomedical Research at MIT. “It will also broaden the biological applications we can explore, especially working in new cell and organoid models.”

The Single Cell Gene Expression LT Kit offers several key features:

• Profiles gene expression for 100 to 1,000 single cells by barcoding mRNA at the 3’ end, allowing unbiased characterization of cell types and states
• Combines gene expression analysis with detection of hundreds of cell surface proteins using oligonucleotide-conjugated antibodies for cellular phenotyping
• Enables cost-effective optimization of experimental conditions and sample prep to maximize the design and impact of single cell experiments 
• Follows a ready-to-use, robust workflow with demonstrated protocols for diverse sample types, including cell lines, primary cells, and dissociated tissue

The 10x Genomics Single Cell Gene Expression LT Kit is available now at https://pages.10xgenomics.com/lt-gene-expression-launch.html, and CellPlex at https://pages.10xgenomics.com/cellplex.html.

About 10x Genomics
10x Genomics is a life science technology company building products to interrogate, understand and master biology to advance human health. The company’s integrated solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. 10x Genomics products have been adopted by researchers around the world, including all of the top 100 global research institutions, as ranked by Nature in 2019, and all of the top 20 global pharmaceutical companies, as ranked by 2019 research and development spend, and have been cited in over 2,250 research papers on discoveries ranging from oncology to immunology, and neuroscience. The company’s patent portfolio comprises more than 1,000 patents and patent applications.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “might," "will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics product performance, configuration and capabilities and adoption. These statements are based on management’s current expectations, forecasts, beliefs, assumptions and information currently available to management, and actual outcomes and results could differ materially from these statements due to a number of factors, including the potential impact of the COVID-19 pandemic. Other risks and uncertainties that could affect 10x Genomics, Inc.’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents 10x Genomics, Inc. files with the Securities and Exchange Commission from time to time. Although 10x Genomics, Inc. believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur. The forward-looking statements in this press release are based on information available to 10x Genomics, Inc. as of the date hereof, and 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward- looking statements should not be relied upon as representing 10x Genomics, Inc.’s views as of any date subsequent to the date of this press release.

Disclosure Information
10x Genomics uses filings with the Securities and Exchange Commission, its website (www.10xgenomics.com), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

Contacts
Media:
media@10xgenomics.com
Investors:
investors@10xgenomics.com